Updates in NHL Management 17+
Med Learning Group
Designed for iPad
-
- Free
Screenshots
Description
This program discusses bispecific antibodies in the management of NHL.
In the management of non-Hodgkin lymphoma (NHL), multiple mechanisms of therapy have been developed. These therapies include anti-CD20 antibodies and chimeric antigen receptor T-cell (CAR-T) therapies. With continued developments in NHL management, bispecific antibodies are a promising strategy for use in the relapsed/refractory setting with promising data showing potential for improving outcomes in patient care.
App Privacy
The developer, Med Learning Group, indicated that the app’s privacy practices may include handling of data as described below. For more information, see the developer’s privacy policy.
Data Not Collected
The developer does not collect any data from this app.
Privacy practices may vary based on, for example, the features you use or your age. Learn More
Information
- Provider
- UMA MLG, LLC has not identified itself as a trader for this app. If you are a consumer in the European Economic Area, consumer rights do not apply to agreements between you and the provider.
- Size
- 96.9 MB
- Category
- Medical
- Compatibility
-
- iPhone
- Requires iOS 11.0 or later.
- iPad
- Requires iPadOS 11.0 or later.
- iPod touch
- Requires iOS 11.0 or later.
- Mac
- Requires macOS 11.0 or later and a Mac with Apple M1 chip or later.
- Languages
-
English
- Age Rating
- 17+ Frequent/Intense Medical/Treatment Information
- Copyright
- © 2023 UMA MLG, LLC
- Price
- Free